1. Ganesh, S. K. et al. Association of elevated serum PO(4), Ca xPO(4) product, and parathyroid hormone with cardiac mortality risk in chronichemodialysis patients. J. Am. Soc. Nephrol. 12, 2131–2138 (2001).
2. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Working Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int. Suppl. 113, S1–S130 (2009).
3. Madorin, C. et al. The surgical management of renal yperparathyroidism. Eur. Arch. Otorhinolaryngol. 269, 1565–1576 (2012).
4. Zhang, Z., Wang, Q. & Liu, Y. Different treatments for secondary hyperparathyroidism of end-stage renal disease. Int. Med. health Guidance News. 19, 3322–3325 (2013b).
5. Komaba, H. et al. Cost-effectiveness of cinacalcet hydrochloride for hemodialysis patients with severe secondary hyperparathyroidism in Japan. Am. J. Kidney Dis. 60(2), 262–271 (2012).